Sutro Biopharma Faces Rising Operational Risks Amid Escalating U.S.-China Trade Tensions
TipRanks (Wed, 25-Mar 2:00 AM ET)
Analysts Are Bullish on These Healthcare Stocks: Sutro Biopharma (STRO), Context Therapeutics (CNTX)
TipRanks (Mon, 23-Mar 6:50 PM ET)
Sutro Biopharma Ends ATM Agreement After 2025 Results
TipRanks (Mon, 23-Mar 5:08 PM ET)
Sutro Biopharma GAAP EPS of -$22.49 misses by $7.28, revenue of $102.48M beats by $3.3M
Seeking Alpha News (Mon, 23-Mar 4:14 PM ET)
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights
Globe Newswire (Mon, 23-Mar 4:05 PM ET)
Sutro Biopharma to Participate in Upcoming Investor Conferences
Globe Newswire (Wed, 25-Feb 8:30 AM ET)
Sutro Biopharma Announces Participation at the 16th World ADC London Summit
Globe Newswire (Mon, 23-Feb 8:30 AM ET)
Market Chameleon (Tue, 10-Feb 4:41 AM ET)
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering
Globe Newswire (Tue, 10-Feb 7:00 AM ET)
Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
Globe Newswire (Wed, 7-Jan 4:05 PM ET)
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Sutro Biopharma trades on the NASDAQ stock market under the symbol STRO.
As of March 27, 2026, STRO stock price declined to $24.43 with 87,771 million shares trading.
STRO has a beta of 3.21, meaning it tends to be more sensitive to market movements. STRO has a correlation of 0.28 to the broad based SPY ETF.
STRO has a market cap of $404.74 million. This is considered a Small Cap stock.
Last quarter Sutro Biopharma reported $12 million in Revenue and -$5.29 earnings per share. This beat revenue expectation by $3 million and missed earnings estimates by -$.77.
In the last 3 years, STRO traded as high as $61.30 and as low as $5.23.
The top ETF exchange traded funds that STRO belongs to (by Net Assets): VTI, VXF, IWC, PRFZ, BIB.
STRO has outperformed the market in the last year with a price return of +219.2% while the SPY ETF gained +12.8%. STRO has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +112.6% and -0.1%, respectively, while the SPY returned -7.9% and -4.5%, respectively.
STRO support price is $23.17 and resistance is $26.65 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STRO shares will trade within this expected range on the day.